REAL

The Impact of Trimetazidine on Disease Severity and Quality of Life in Parkinson's Disease

Pintér, Dávid and Juhász, Annamária and Harmat, Márk and Janszky, József Vladimír and Kovács, Norbert (2020) The Impact of Trimetazidine on Disease Severity and Quality of Life in Parkinson's Disease. SCIENTIFIC REPORTS, 10 (1). ISSN 2045-2322

[img]
Preview
Text
2020_ScientificReports_TMZ_Severity.pdf

Download (939kB) | Preview

Abstract

Trimetazidine is contraindicated in movement disorders, however, a not negligible part of trimetazidine users is still patients with Parkinson's disease (PD). The present study aimed to objectively determine the impact of trimetazidine on the severity of symptoms and the health-related quality of life of patients with PD by measuring changes after its withdrawal. A consecutive series of 42 patients with PD using trimetazidine underwent detailed neurological and neuropsychological assessments at baseline and three months after the discontinuation of trimetazidine. Clinically relevant improvements were achieved with discontinuation of trimetazidine according to changes in scores of each part of the Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale (Part I: -25.7%, p < 0.001; Part II: -23.8%, p < 0.001; Part III: -28.5%, p < 0.001; Part IV: -30.1%, p = 0.004) and total scores of the Non-Motor Symptoms Scale (-25.6%, p = 0.004) and the Montgomery-Asberg-Depression Rating Scale (-20.1%, p = 0.001). Benefits resulting from the withdrawal of the drug also manifested in the improvement of the health-related quality of life based on changes in the summary index of the 39-item Parkinson's Disease Questionnaire (-18.2%, p = 0.031). Our results provide clinical rationale for strictly avoiding the use of trimetazidine in PD. Discontinuation of trimetazidin results in clinically relevant improvements in Parkinsonian symptoms.

Item Type: Article
Additional Information: Export Date: 29 June 2020 Funding Agency and Grant Number: Hungarian Brain Research Program [2017-1.2.1-NKP-2017-00002, EFOP-3.6.1-16-2016-00004]; NKFIH [SNN125143, EFOP-3.6.2-16-2017-00008]; Higher Education Institutional Excellence Program of the Ministry of Human Capacities in Hungary [20765/3/2018/FEKUSTRAT]; Hungarian subsidiary of AbbVie; AbbVie; UCBUCB Pharma SA; Valeant; Gerot; MedtronicMedtronic; Boehringer IngelheimBoehringer Ingelheim; NovartisNovartis; GlaxoSmithKlineGlaxoSmithKline; Krka Funding text: This study was supported by the Hungarian Brain Research Program (2017-1.2.1-NKP-2017-00002), EFOP-3.6.1-16-2016-00004, NKFIH EFOP-3.6.2-16-2017-00008, and NKFIH SNN125143 government-based funds. Our research was partly financed by the Higher Education Institutional Excellence Program of the Ministry of Human Capacities in Hungary, within the framework of the 5th thematic program of the University of Pecs, Hungary (20765/3/2018/FEKUSTRAT). AJ received <1000 EUR congress participation support from Hungarian subsidiary of AbbVie. JJ received <1000 EUR consultation fees from Hungarian subsidiaries of UCB, Valeant and Gerot. NK received <1000 EUR consultation fees from Hungarian subsidiaries of Medtronic, Boehringer Ingelheim, Novartis, GlaxoSmithKline, UCB, Krka and Abbvie. Regarding this study, the authors did not receive any corporate funding. DP and MH reported no financial disclosure. Department of Neurology, University of Pécs, Medical School, Pécs, Hungary MTA-PTE Clinical Neuroscience MR Research Group, Pécs, Hungary Export Date: 9 October 2020 Correspondence Address: Pintér, D.; Department of Neurology, University of Pécs, Medical SchoolHungary; email: david_pinter@outlook.com Funding Agency and Grant Number: Hungarian Brain Research Program [2017-1.2.1-NKP-2017-00002, EFOP-3.6.1-16-2016-00004]; NKFIH [SNN125143, EFOP-3.6.2-16-2017-00008]; Higher Education Institutional Excellence Program of the Ministry of Human Capacities in Hungary [20765/3/2018/FEKUSTRAT]; Hungarian subsidiary of AbbVie; AbbVie; UCBUCB Pharma SA; Valeant; Gerot; MedtronicMedtronic; Boehringer IngelheimBoehringer Ingelheim; NovartisNovartis; GlaxoSmithKlineGlaxoSmithKline; Krka Funding text: This study was supported by the Hungarian Brain Research Program (2017-1.2.1-NKP-2017-00002), EFOP-3.6.1-16-2016-00004, NKFIH EFOP-3.6.2-16-2017-00008, and NKFIH SNN125143 government-based funds. Our research was partly financed by the Higher Education Institutional Excellence Program of the Ministry of Human Capacities in Hungary, within the framework of the 5th thematic program of the University of Pecs, Hungary (20765/3/2018/FEKUSTRAT). AJ received < 1000 EUR congress participation support from Hungarian subsidiary of AbbVie. JJ received < 1000 EUR consultation fees from Hungarian subsidiaries of UCB, Valeant and Gerot. NK received < 1000 EUR consultation fees from Hungarian subsidiaries of Medtronic, Boehringer Ingelheim, Novartis, GlaxoSmithKline, UCB, Krka and Abbvie. Regarding this study, the authors did not receive any corporate funding. DP and MH reported no financial disclosure.
Subjects: R Medicine / orvostudomány > RC Internal medicine / belgyógyászat > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry / idegkórtan, neurológia, pszichiátria
SWORD Depositor: MTMT SWORD
Depositing User: MTMT SWORD
Date Deposited: 04 Jan 2021 14:55
Last Modified: 04 Jan 2021 14:55
URI: http://real.mtak.hu/id/eprint/119050

Actions (login required)

Edit Item Edit Item